Kanaly Trust’s Myriad Genetics MYGN Stock Holding History

Kanaly Trust’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-61	Closed	-$2K	–	770
2014 Q3	$2K	Buy	+61	New	+$2.28K	﹤0.01%	721

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BTS

BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kanaly Trust's MYGN Position: Q4 2014 in Review

Kanaly Trust sold out of Myriad Genetics (MYGN) in Q4 2014, closing a stake of 61 shares — an estimated $2K sold.

Kanaly Trust first reported a position in MYGN in Q3 2014 and held it in 1 quarter. The position peaked at $2K in Q3 2014. 272 funds tracked by Wall St. Rank hold MYGN as of Q4 2014.

Kanaly Trust reported no remaining Myriad Genetics position as of Q4 2014 after selling out during the quarter.
Kanaly Trust sold 61 Myriad Genetics shares in Q4 2014, an estimated $2K.
Kanaly Trust first reported a position in Myriad Genetics in Q3 2014 and held it in 1 quarter.
Kanaly Trust's Myriad Genetics position peaked at $2K in Q3 2014.
272 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2014.

Based on Kanaly Trust's 13F filing for Q4 2014, filed 26 Jan 2015.